Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world. The Group’s unique governance model ensures its independence while fostering long‑term innovation, with 100% of its profits reinvested in the company’s development. As a world leader in cardiometabolism and venous diseases, Servier drives transformative innovation in chronic conditions through a holistic approach, making patient adherence a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are targeted and effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group focuses on a select number of neurodegenerative diseases, where acc...